The independent director control over proceeds and the consistent $50,000/unit valuation across two recent transactions suggest a deliberate capital raise structure. Monitor for further unit sales or a potential full exit of the subsidiary. The CEO's personal investment aligns his interests with minority shareholders but does not change the company's operational outlook.
Price Chart
Executive Summary
Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell seven units (7% membership interest) of its subsidiary Adia Labs LLC to its CEO, Larry A. Powalisz, for $350,000 in cash. The proceeds are controlled by independent directors, not the CEO, mitigating self-dealing concerns. This follows a prior 8-K (Oct 6) where Adia sold a 30% stake in the same subsidiary to Live Oak Health LLC for $1.5M, indicating a pattern of monetizing the subsidiary.
Key Financial Metrics
Key Facts
- Adia Med sold 7 units (7% membership interest) of Adia Labs LLC to CEO Larry A. Powalisz for $350,000 in cash.
- The purchase price is $50,000 per unit, same per-unit price as the prior 30% sale to Live Oak Health LLC on September 30, 2026.
- Proceeds from the sale can only be used for corporate purposes as jointly approved by both independent directors, Monica Sher, M.D., and Richard Edwards, D.O.
- The CEO has no unilateral authority over the use of the proceeds.
- The agreement was signed on October 13, 2026, and filed on October 19, 2026.
Financial Impact
Adia Med received $350,000 in cash for a 7% stake in its subsidiary Adia Labs LLC. Combined with the prior $1.5M sale of 30% to Live Oak, the subsidiary has been valued at $5M (100 units at $50,000/unit).
Risk Factors
- Related-party transaction with the CEO creates potential conflicts of interest, though independent director oversight mitigates this.
- Dilution of Adia Med's ownership in Adia Labs LLC from 100% to 63% after both transactions (30% to Live Oak + 7% to CEO).
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007951 |
| Document: adia_8k.htm | 0001683168-26-007951 |
| Document: 0001683168-26-007951-index-headers.html | 0001683168-26-007951 |
| Document: 0001683168-26-007951-index.html | 0001683168-26-007951 |
| Document: 0001683168-26-007951.txt | 0001683168-26-007951 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.1300 | awaiting T+20 | — | $0.1100 (−15.38%) |
Oct 13, 2026 13d ago | 8-K | $0.1470 | awaiting T+20 | — | $0.1100 (−25.17%) |
Oct 5, 2026 20d ago | 8-K | $0.1480 | awaiting T+20 | — | $0.1100 (−25.68%) |
Oct 5, 2026 20d ago | 8-K | $0.1480 | awaiting T+20 | — | $0.1100 (−25.68%) |
Aug 24, 2026 9w ago | 8-K | $0.1170 $0.1450 | ▲ +23.93% | ▲ +23.92% | $0.1100 (−5.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers